

DAFTAR PUSTAKA

- Allison, S. L., Stiasny, K., Stadler, K., Mandl, C. W., Heinz, F. X. 1999. Mapping of functional elements in the stem-anchor region of tick-borne encephalitis virus envelope protein E. *J Virol.* 73: 5605–5612.
- Alvarez, D. E., Filomatori, C. V., Gamarnik, A. V. 2008. Functional analysis of dengue virus cyclization sequences located at the 5' and 3'UTRs. *Virology.* 375: 223–235
- Beatty, M. E. Stone, A. Fitzsimons, D. W. Hanna, J. N. Lam, S. K. Vong S., et. al. 2010. Best Practices In Dengue Surveillance: A Report From The Asia-Pacific And Americas Dengue Prevention Boards. *PLoS Negl Trop Dis.* 4(11).
- Borsuk, S., Seixas, F. K., Ramos, D. F., Mendum, T., McFadden, J., Dellagostin, O. 2012. Rational design of diagnostic and vaccination strategies for tuberculosis. *Braz J Infect Dis.* 16(1): 68-73.
- Burgos, G. S., J. Ramos-Castañeda, R. Cedillo-Rivera, E. Dumonteil. 2010. Immunogenicity of novel Dengue virus epitopes identified by bioinformatic analysis. *Virus Research.* 153: 113–120.
- Caufour, P.S., M.C.A., Motta, A.M.Y. Yamamura, S. Vazquez, I.I. Ferreira, A.V. Jabor, M.C. Bonaldo, M.S. Freire, R. Galler. 2001. Construction, characterization and immunogenicity of recombinant yellow fever 17D-dengue type 2 virus. *Virus Research.* 79: 1–14
- Chou, P.Y. and Fasman, G. D. 1978. Prediction of the secondary structure of proteins from their amino acid sequence. *Adv Enzymol Relat Areas Mol Biol.* 47: 45-148.
- De groot, A. S., Bosma, A., Chinai, N. 2001. From genome to vaccine: In silico predictions, ex vivo verification. *Vaccine.* 19: 4385-4395.
- [Desai, D. V.](#), and [Kulkarni-Kale, U.](#) 2014. T-cell epitope prediction methods: an overview. *Methods Mol Biol.* 1184: 333-64.
- Emini EA, Hughes JV, Perlow DS, Boger J. 1985. Induction of hepatitis A virus-neutralizing antibody by a virus-specific synthetic peptide. *J Virol.* 55(3):836-9.
- Estrada, S. F. L, M. Y. Monroy, R. M. del Angel. 2010. Insights into dengue virus genome replication. *Future Virol.* 5: 575–592

Gededzha, Maemu P., M Jeffrey Mphahlele, Selokela G Selabe. 2014. Prediction of T-cell epitopes of hepatitis C virus genotype 5a. *Virology Journal*. 11:187

Guirakhoo, F., J. Arroyo, K.V. Pugachev, C. Miller, Z.-X. Zhang, R. Weltzin, K. Georgakopoulos, J. Catalan, S. Ocran, K. Soike, M. Ratterree, and T. P. Monath. 2001. Construction, Safety, and Immunogenicity in Nonhuman Primates of a Chimeric Yellow Fever-Dengue Virus Tetravalent Vaccine. *Journal of virology*, 75 (6): 7290–7304.

Halstead S. B., 1988. Pathogenesis of dengue: challenges to molecular biology. *Science*. 239: 476–81

_____. 2007. Dengue. *Lancet*. 370: 1644–52

Herrero, L. J., A. Zakhary, M. E. Gahan, M. A. Nelson, B. L. Herring, A. J. Hapel, et al. 2013. Dengue Virus Therapeutic Intervention Strategies Based On Viral, Vector And Host Factors Involved In Disease Pathogenesis. *Pharmacology & Therapeutics*. 137: 266–282

Izabela, A. R. Z., J. Wilschut. J. M. Smit. 2010. Dengue virus life cycle: viral and host factors modulating infectivity. *Cell. Mol. Life Sci*. 67:2773–2786

Larsen, J. E. P., Lund, O., and Nielsen, M. 2006. Improved method for predicting linear B-cell epitopes. *Immunome Res.*; 2: 2.

Kanesa-athan, N., Sun, W., Kim-Ahn, G., Van Albert, S., Putnak, J. R., King, A., et al. 2001. Safety and Immunogenicity of Attenuated Dengue Virus Vaccines (Aventis Pasteur) in Human Volunteers. *Vaccine*. 19: 3179–3188.

Karplus, P.A., Schulz, G.E. 1985. Prediction of Chain Flexibility in Proteins - A tool for the Selection of Peptide Antigens. *Naturwissenschaften*. 72:212-3.

Khan, A.M., Miotto, O., Heiny, A.T., et al. 2006. A systematic bioinformatics approach for selection of epitope-based vaccine targets. *Cellular Immunol*. 244: 141–147.

Kolaskar AS, Tongaonkar PC. A semi-empirical method for prediction of antigenic determinants on protein antigens. *FEBS Lett*. 1990 Dec 10;276(1-2):172-4.

Kyte, J. and Doolittle, R. F. 1982. A simple method for displaying the hydropathic character of a protein. *J Mol Biol*. 157(1): 105--132.

Kuhn, R. J., W. Zhang, M. G. Rossmann. 2002. Structure of dengue virus: implications for flavivirus organization, maturation, and fusion. *Cell*. 108: 717–725



- Lai, C. Y., Tsai, W. Y., Lin, S. R., Kao, C. L., Hu, H. P., et al. 2008. Antibodies to envelope glycoprotein of dengue virus during the natural course of infection are predominantly cross-reactive and recognize epitopes containing highly conserved residues at the fusion loop of domain II. *J Virol.* 82: 6631–6643.
- Li, L., S. M. Lok, I. M. Yu. 2008. The flavivirus precursor membrane–envelope protein complex: structure and maturation. *Science.* 319: 1830–1834
- Lodeiro MF, Filomatori C, Gamarnik AV. 2009. Structural and functional studies of the promoter element for dengue virus RNA replication. *J. Virol.* 83: 93–1008
- Lua, H., X. F. Xub, N. Gaoa, D. Y. Fana, J. Wanga, J. Ana. 2013. Preliminary evaluation of DNA vaccine candidates encoding dengue-2 prM/E and NS1: Their immunity and protective efficacy in mice. *Molecular Immunology.* 54: 109– 114
- Modis, Y., Ogata S., Clements D., Harrison S. C. 2003. A ligand-binding pocket in the dengue virus envelope glycoprotein. *Proc Natl Acad Sci USA.* 100: 6986–6991
- Mosimann, A. L. P., L. de Borbaa, J. Bordignona, P. W. Masonb, C. N. D. dos Santos. 2010. Construction and characterization of a stable subgenomic replicon system of a Brazilian dengue virus type 3 strain (BR DEN3 290-02). *Journal of Virological Methods.* 163: 147–152
- Osorio, J. E., Brewoo, J. N., Silengo, S. J., Arguello, J., Moldovan, I. R., Tary-Lehmann, M., et. al. 2011. Efficacy of a Tetravalent Chimeric Dengue Vaccine (DENVax) in Cynomolgus Macaques. *Am J Trop Med Hyg.* 84: 978–987
- Oyarzún, P., Ellis, P. J., BodÈn, M., Kobe, B. 2013. PREDIVAC: CD4+ T-cell epitope prediction for vaccine design that covers 95% of HLA class II DR protein diversity. *BMC Bioinformatics.* 14:52.
- Parker, J.M., Guo, D., Hodges, R.S. 1986. New hydrophilicity scale derived from high-performance liquid chromatography peptide retention data: correlation of predicted surface residues with antigenicity and X-ray-derived accessible sites. *Biochemistry.* 23:25
- Patronov, A., and Doytchinova, I. 2013. T-cell epitope vaccine design by immunoinformatics. *Open Biology.*
- Perera, R., and Kuhn, R. J. 2008. Structural proteomics of dengue virus. *Curr Opin Microbiol.* 11: 369–77
- Ponomarenko, J. V. and Regenmortel, M. H. V. 2009. *B-cell epitope prediction.* Structural Bioinformatics. 2: 849-879



- Puttikhunt, C., P. Keelapang, N. Khemnu, N. Sittisombut, W. Kasinrer, P. Malasit. 2008. Novel Anti-Dengue Monoclonal Antibody Recognizing Conformational Structure of the prM-E Heterodimeric Complex of Dengue Virus. *Journal of Medical Virology*. 80: 125–133
- Rice, C.M., Lenches, E., Eddy, S.R., Shin, S.J., Sheets, R.L., Strauss, J.H., 1985. Nucleotide sequence of yellow fever virus: implications for flavivirus gene expression and evolution. *Science*. 229: 726–733
- Rothman, A. 2011. Immunity to Dengue Virus: A Tale of Original Antigenic Sin and Tropical Cytokine Storms. *Nat Rev Immunol*. 11: 532–543
- Sette, A., Livingston, B., McKinney, D., Appella, E., Fikes, J., et al. 2001. The development of multi-epitope vaccines: epitope identification, vaccine design and clinical evaluation. *Biologicals*. 29: 271-276.
- Soares, R.O.S. and Caliri, A. 2013. Stereochemical features of the envelope protein Domain III of dengue virus reveals putative antigenic site in the five-fold symmetry axis. *Biochimica et Biophysica Acta*. 1834: 221–230
- Somvanshi, P., and Seth, P. K. 2009. Prediction of T cell epitopes for the utility of vaccine development from structural proteins of dengue virus variants using in silico methods. *Indian J. of Biotech*. 8: 193-198.
- Song, K. Y., H. Zhao, S. H. Li, et al., 2013. Identification and characterization of a linearized B-cell epitope on the pr protein of dengue virus. *Journal of General Virology*. 94: 1510-1516
- Srivastava, A.K., Putnak, J.R., Warren, R.L., Hoke, C.H. Jr., 1995. Mice immunized with a dengue type 2 virus E and NS1 fusion protein made in *Escherichia coli* are protected against lethal dengue virus infection. *Vaccine*. 13:1251–1258.
- Tajima, S., Nukui, Y., Takasaki, T. 2007. Characterization of the variable region in the 3' non-translated region of dengue type 1 virus. *J. Gen. Virol*. 88: 2214–2222
- Vajda, S., R. Kataoka, and C. DeLisf. 1990. Molecular Structure and Vaccine Design. *Annu. Rev. Biophys. Biophys. Chem*. 19:69-82
- Villordo, S. M., Gamarnik, A. V., 2009. Genome cyclization as strategy for flavivirus RNA replication. *Virus Res*. 139: 230–239
- Wen, J.S., Jiang, L.F., Zhou, J.M., et al. 2007. Computational prediction and identification of dengue virus-specific CD4+ T-cell epitopes. *Virus Res*. 132: 42–48.



Welling GW, Weijer WJ, van der Zee R, Welling-Wester S. 1985. Prediction of sequential antigenic regions in proteins. *FEBS Lett.* 188(2): 215–218.

Whitehead, S. S., Falgout, B., Hanley, K. A. 2003. A live, attenuated dengue virus type 1 vaccine candidate with a 30-nucleotide deletion in the 3' untranslated region is highly attenuated and immunogenic in monkeys. *J. Virol.* 77: 1653–1657